Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells.
Frecot DI, Blaess S, Wagner TR, Kaiser PD, Traenkle B, Fandrich M, Jakobi M, Scholz AM, Nueske S, Schneiderhan-Marra N, Gouttefangeas C, Kneilling M, Pichler BJ, Sonanini D, Rothbauer U.
Frecot DI, et al. Among authors: wagner tr.
Front Immunol. 2024 Oct 15;15:1480091. doi: 10.3389/fimmu.2024.1480091. eCollection 2024.
Front Immunol. 2024.
PMID: 39474429
Free PMC article.